HCV genome variability in acute and chronic viral hepatitis C
- 作者: Yushchuk ND1, Klimova EA1, Znoyko OO1, Gadzhikulieva MM1, Il'ina EN1, Yashina TL1, Malyshev NA1, Tsyganova EV1, Yuschuk ND1, Klimova EA1, Znoiko OO1, Gadzhikulieva MM1, Ilyina EN1, Yashina TL1, Malyshev NA1, Tsyganova EV1
-
隶属关系:
- 期: 卷 81, 编号 4 (2009)
- 页面: 47-54
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.04.2009
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30313
- ID: 30313
如何引用文章
全文:
详细
Material and methods. The study of heterogeneity of HCV in acute hepatitis C has detected genetic heterogeneity and variability of individual HCV population circulating in the blood. Significant genetic heterogeneity of HCV was observed in 1b, 2a and 3a genotypes. Variability of HCV did not depend on virus load. Genetic HCV structure changed significantly both in patients with manifest ALT deviations and in normal ALT, mean number of HCV genetic variants in these groups being the same. No significant correlations were found between virus concentration in the patient's blood, its variability and ALT values. Genetic heterogeneity of interferon-sensitive region of gene NS5A subtype 1b HCV was studied in blood of 16 patients with chronic hepatitis C resistant to interferon therapy.
Results. It is shown that genetic heterogeneity and variability of an individual HCV population circulating in blood serum can not be a prognostic criterion in assessment of variants of acute hepatitis C course. No mutations in ISDR region were found in 25% of 16 patients studied. 75% cases had 1-3 replacements of amino acid sequences, most frequent mutation was replacements in position 2218 (histidin/arginin). The above results are close to those obtained in Japanese and European populations.
Results of ISDR sequence-analysis conducted before treatment may predict efficacy of interferon-alpha2 treatment in an individual patient in future. Large-scale trials are necessary for detection of mutations responsible for resistance to interferon-alpha2 in patients living in Russia.
作者简介
N Yushchuk
E Klimova
O Znoyko
M Gadzhikulieva
E Il'ina
T Yashina
N Malyshev
E Tsyganova
N Yuschuk
E Klimova
O Znoiko
M Gadzhikulieva
E Ilyina
T Yashina
N Malyshev
E Tsyganova
参考
- Choo Q. L., Kuo G., Weiner A. J. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
- Clarke B. Molecular virology of hepatitis C virus. J. Gen. Virol. 1997; 78: 2397-2410.
- Purcell R. The hepatitis C virus: overview. Hepatology 1997; 26 (3, suppl. 1): 134-143.
- Farci P. Hepatitis C virus. The importance of viral heterogeneity. Clin. Liver Dis. 2001; 5 (4): 895-916.
- Enomoto N., Sakuma I., Asahina Y. et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A gene. J. Clin. Invest. 1995; 96: 224-230.
- Enomoto N., Sakuma I., Asahina Y. et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334 (2): 77-81.
- Kurosaki M., Enomoto N., Murakami T. et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25 (3): 750-753.
- Khorsi H., Castelain S., Wyseur A. et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J. Hepatol. 1997; 27: 72-77.
- McKechnie V. M., Mills P. R., McCruden E. A. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha. J. Med. Virol. 2000; 60 (4): 367-378.
- Pawlotsky J. M., Germanidis G., Neumann A. U. et al. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations. J. Virol. 1998; 72: 2795-2805.
- Saiz J. C., Lopez Labrador F. X. et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 1998; 177: 839-847.
- Watanabe H., Enomoto N., Nagayama K. et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J. Infect. Dis. 2001; 183: 1195-1203.
- Wohnsland A., Hofmann W. P., Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 2007; 20 (1): 23-38.
- Zeuzem S., Lee J. H., Roth W. K. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740-744.
- Pascu M., Martus P., Hцhne M. et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53 (9): 1345-1351.
补充文件
![](/img/style/loading.gif)